- CH₣252.66bn
- CH₣285.31bn
- $56.33bn
Corrected: UPDATE 3-Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11)
US FDA approves Scholar Rock's muscle weakness drug
US stocks weekly: Yields bite
For Novartis, M&A is both a disease and cure
Focus: Novartis investors turn spotlight on M&A after trial setbacks
Major Novartis shareholder calls for board shake-up after drug trial setbacks
Major Novartis shareholder calls for board shake-up after drug trial setbacks
Europe Research Roundup: AstraZeneca, GSK, Kingspan Group
Roche's sustained growth visibility, Novartis' execution risks - RBC initiates coverage
Swiss stocks - Factors to watch on September 9
Asia Morning Call-Global Markets (updated)
Live Markets: Back to the post-summer grind: Stocks end red
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
European shares muted as oil rally fuels caution; Novartis tumbles (updated)
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Sarepta, Dyne fall after Novartis muscle disorder trial failure
Sarepta, Dyne sink after Novartis muscle disorder trial failure
Ionis Pharma tumbles after heart drug fails late-stage trial
Amgen falls after Novartis trial setback, BMO downgrade